title: Initial cytomegalovirus prophylaxis with ganciclovir: no guarantee for prevention of late serious manifestations of CMV after solid organ transplantation.
abstract: A 37-year-old woman presented with malaise, upper abdominal pain and fever seven months after renal transplantation. She was seronegative for cytomegalovirus (CMV) and had received a kidney from a seropositive donor. She had received CMV prophylaxis (oral ganciclovir) for three months after transplantation. During this period all tests for CMV remained negative. On admission, she presented with symptoms compatible with an acute abdomen and with deterioration of renal function. On emergency laparotomy a perforation of the ileum was found. The resected specimen showed an ulcer with vasculitis at the site of perforation, with both microscopic (owl's eye inclusion bodies), as well as immunohistochemical evidence for a CMV infection. CMV can reactivate (usually in the first three months) after transplantation, sometimes resulting in serious morbidity. The use of antiviral prophylaxis during and after transplantation has certainly decreased the number and severity of CMV infections. This case illustrates that life-threatening infections such as CMV can still emerge a long time after transplantation. Unrelenting awareness of this condition is mandatory, even after apparently adequate anti-CMV prophylaxis.
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Groningen University Medical Centre, Groningen, the Netherlands. marietzandberg@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Zandberg
authors.forename: E F
authors.initials: EF
authors.lastname: de Maar
authors.forename: H S
authors.initials: HS
authors.lastname: Hofker
authors.forename: J J
authors.initials: JJ
authors.lastname: Homan van der Heide
authors.forename: S
authors.initials: S
authors.lastname: Rosati
authors.forename: W J
authors.initials: WJ
authors.lastname: van Son
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D013997:Time Factors; D014775:Virus Activation
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir